MedPath

Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations

Recruiting
Conditions
Cerebral Arteriovenous Malformations
Ruptured or Unruptured Cerebral Arteriovenous Malformations
Registration Number
NCT03676868
Lead Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Brief Summary

The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation.

The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke.

The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Patient over 18 years old
  • Patient with a cerebral AVM for which an intervention (endovascular treatment or surgery) or only clinical monitoring
  • Express consent to participate in the study

And

  • children
  • Free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority
Exclusion Criteria
  • Patient benefiting from a legal protection measure
  • Pregnant or breast feeding woman

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic6 months

associaton between dosage of endothelial marker in blood samples and correlation with clinical outcome

Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic6 months

Dosage of neutrophilic in blood samples and correlation with clinical outcome

Associaton between dosage of platelet and the arteriovenous malformation pronostic6 months

Dosage of platelet in blood samples and correlation with clinical outcome

Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic6 months

Dosage neo-angiogenesis activation markers in blood samples and correlation with clinical outcome

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Fondation Ophtalmologique Rotschild

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath